Matthew M. Walsh - 31 Mar 2025 Form 4 Insider Report for Organon & Co. (OGN)

Role
Chief Financial Officer
Signature
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Matthew M. Walsh
Issuer symbol
OGN
Transactions as of
31 Mar 2025
Transactions value $
-$249,195
Form type
4
Filing time
02 Apr 2025, 17:41:53 UTC
Previous filing
24 Feb 2025
Next filing
06 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OGN Common Stock Options Exercise $0 +15.1K +13.06% $0.00 130K 31 Mar 2025 Direct
transaction OGN Common Stock Tax liability -$108K -7.42K -5.69% $14.51 123K 31 Mar 2025 Direct F1
transaction OGN Common Stock Options Exercise $0 +12K +9.79% $0.00 135K 31 Mar 2025 Direct
transaction OGN Common Stock Tax liability -$86.1K -5.93K -4.39% $14.51 129K 31 Mar 2025 Direct F1
transaction OGN Common Stock Options Exercise $0 +7.75K +6% $0.00 137K 31 Mar 2025 Direct
transaction OGN Common Stock Tax liability -$55.4K -3.82K -2.79% $14.51 133K 31 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Stock Option (right to buy) Award $0 +318K $0.00 318K 31 Mar 2025 Common Stock 318K $14.89 Direct F2
transaction OGN Restricted Stock Units Award $0 +64.6K $0.00 64.6K 31 Mar 2025 Common Stock 64.6K Direct F3, F4
transaction OGN Restricted Stock Units Options Exercise $0 -15.1K -33.33% $0.00 30.1K 31 Mar 2025 Common Stock 15.1K Direct F3, F5
transaction OGN Restricted Stock Units Options Exercise $0 -12K -50% $0.00 12K 31 Mar 2025 Common Stock 12K Direct F3, F6
transaction OGN Restricted Stock Units Options Exercise $0 -7.75K -100% $0.00 0 31 Mar 2025 Common Stock 7.75K Direct F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
F2 The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028.
F3 Each RSU converts into one share of Organon common stock.
F4 The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028.
F5 On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.
F6 On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026.
F7 On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested.